Current challenges in the treatment of high-risk non-metastatic RCC

"These final analysis results of LITESPARK-005 support belzutifan as a treatment option in refractory kidney cancer after checkpoint inhibitor and VEGFR-TKI therapy," says Brian Rini, MD.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

“Over the 4-year period since first-line protocol therapy initiation, [patients treated with] nivolumab plus cabozantinib achieved a 1.5-times longer mean TFS vs sunitinib," says Charlene Mantia, MD.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

No statistically significant difference was seen in progression-free survival among those who received metformin vs those who received placebo.

“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.